Antiphospholipid antibodies in patients with coronavirus disease 2019 infection hospitalized in conventional unit.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
01 Mar 2021
01 Mar 2021
Historique:
pubmed:
5
12
2020
medline:
20
2
2021
entrez:
4
12
2020
Statut:
ppublish
Résumé
Antiphospholipid (aPL) antibodies can arise transiently at times of viral diseases. The objective of this work was to evaluate the incidence of aPL antibodies in patients hospitalized in conventional unit for coronavirus disease 2019 (COVID-19) infection and confirmed venous thromboembolic events (VTE) associated with aPL antibodies. 41 patients infected with COVID-19 were tested for aPL antibodies. None had reported history of aPL syndrome. Arterial and venous duplex ultrasound of lower limbs was performed in all patients at Day 0 and Day 5. All patients had antithrombotic-prophylaxis upon admission using lower molecular weight heparin with Enoxaparin. Biological parameters were collected and analyzed. Nine patients (22%) developed VTE and seven (17%) were positive for aPL antibodies of which five had isolated positive lupus anticoagulant. The sixth patient was double aPL positive IgM anticardiolipin (147.8 U/ml) and anti-Beta2 Glyco protein 1 (97.3 U/ml) antibodies. The seventh was triple positive, IgM anticardiolipin 85.6 UI/ml, IgM anti-Beta2 Glyco protein 1 63.0 U/ml and positive lupus anticoagulant. Among the seven patients with aPL antibodies 2 (28.60%) had VTE. However, the incidence of VTE in patients negative for aPL antibodies was also significant as 20.6% (seven of 34). aPL antibodies were significantly associated with the transfer to ICUs of, P = 0.018. Not only the incidence of aPL antibodies was quite significant within our cohort, but also we observed 28.6% of VTE in aPL-positive patients. We strongly recommend routine testing for aPL antibodies in COVID-19 patients and systematic screening with duplex ultrasound search of vascular complications.
Identifiants
pubmed: 33273262
pii: 00001721-202103000-00001
doi: 10.1097/MBC.0000000000000963
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Anticoagulants
0
Enoxaparin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
73-79Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Références
Kuteifan K, Pasquier P, Meyer C, Escarment J, Theissen O. The outbreak of COVID-19 in Mulhouse: hospital crisis management and deployment of military hospital during the outbreak of COVID-19 in Mulhouse, France. Ann Intensive Care 2020; 10:59.
Lodigiani C, Iapichino G, Carenzo L, Cecconi M, Ferrazzi P, Sebastian T, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020; 191:9–14.
Wool G, Reyes Gil M, Lee A, Key N, Sabath D, Leissinger C, et al. COVID-19 and aPL Ab - Hematology.org [Internet]. [cited 2020 May 11]. Available from: https://www.hematology.org/covid-19/covid-19-and-apl-ab .
Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020; 382:e38.
La société d’Imagerie Thoracique propose un compte-rendu structuré de scanner thoracique pour les patients suspects de COVID-19 [Internet]. SFR e-Bulletin. 2020. Available from: https://ebulletin.radiologie.fr/actualites-covid-19/societe-dimagerie-thoracique-propose-compte-rendu-structure-scanner-thoracique . [Cited 29 April 2020].
Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in false negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med 2020; M20–M1495. doi: 10.7326/M 20-1495.
doi: 10.7326/M
Pengo V. ISTH guidelines on lupus anticoagulant testing. Thromb Res 2012; 130: (Suppl 1): S76–S77.
Schouwers SME, Delanghe JR, Devreese KMJ. Lupus anticoagulant (LAC) testing in patients with inflammatory status: does C-reactive protein interfere with LAC test results? Thromb Res 2010; 125:102–104.
Cervera R. Antiphospholipid syndrome. Thromb Res 2017; 151: (Suppl 1): S43–S47.
Abdel-Wahab N, Talathi S, Lopez-Olivo MA, Suarez-Almazor ME. Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta-analysis. Lupus 2018; 27:572–583.
Galrão L, Brites C, Atta ML, Atta A, Lima I, Gonzalez F, et al. Antiphospholipid antibodies in HIV-positive patients. Clin Rheumatol 2007; 26:1825–1830.
Goeijenbier M, van Wissen M, van de Weg C, Jong E, Gerdes VEA, Meijers JCM, et al. Review: viral infections and mechanisms of thrombosis and bleeding. J Med Virol 2012; 84:1680–1696.
Helms J, Tacquard C, Severac F, Leonard-Lorant I, Ohana M, Delabranche X, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46:1089–1098.
Bowles L, Platton S, Yartey N, Dave M, Lee K, Hart DP. Lupus anticoagulant and abnormal coagulation tests in patients with covid-19. N Engl J Med 2020; 383:288–290.
Harzallah I, Debliquis A, Drenou B. Lupus anticoagulant is frequent in patients with Covid-19. J Thromb Haemost 2020; 18:2064–2065.
Pengo V, Testa S, Martinelli I, Ghirarduzzi A, Legnani C, Gresele P, et al. Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 2014; 135:46–49.
Galeano-Valle F, Oblitas CM, Ferreiro-Mazón MM, Alonso-Muñoz J, Del Toro-Cervera J, di Natale M, et al. Antiphospholipid antibodies are not elevated in patients with severe COVID-19 pneumonia and venous thromboembolism. Thromb Res 2020; 192:113–115.
Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020; 18:1421–1424.
2020; Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. 8: Available from: https://www.researchsquare.com/article/rs-20850/v1 . [Cited 29 May 2020].
Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med 2020; 8:e46–e47.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Annelies S, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet 2020; 395:1417–1418.